Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal clinical trials have evolved, the stratification of patients by homologous recombination deficiency (HRD) and BRCA mutation…
Long-Term OS Data Guide Use of PARP Inhibitors in Ovarian Cancer | Targeted Oncology
